Key financial results
- Fourth quarter revenue was $126.6 million, representing a 28% increase year-over-year.
This is our 15th consecutive quarter of sequential growth.
- Full year revenue reached $459.4 million, which was 22% higher than the previous year.
Full year revenue reached almost $460 million, up 22% and more than $30 million above our initial 2026 guidance.
- The company achieved positive adjusted EBITDA of $2.2 million in the fourth quarter.
Fourth quarter adjusted EBITDA was positive at $2.2 million, delivering the milestone we committed to several years ago.
- Full year gross margin was 52.4%, compared to 50.7% in fiscal 2025.
Full year gross margin reached 52.4%.
- The company ended the fiscal year with $582 million in cash, cash equivalents, and short-term investments.
Business segment results
- DNA Synthesis and Protein Solutions: DNA Synthesis and Protein Solutions revenue was $61 million in the fourth quarter, up 33% year-over-year.
- NGS Applications: NGS applications revenue was $65.7 million in the fourth quarter, an increase of 24% year-over-year.
- Therapeutics: Therapeutics revenue grew 44% year-over-year to $43.9 million in the fourth quarter.
- AI Drug Discovery: AI drug discovery revenue grew 175% to $59.1 million for the full year, up from $21.5 million in fiscal 2025.
- Diagnostics: Diagnostics revenue was $45.2 million in the fourth quarter, a 23% increase.
- Academic and Government: Academic and government revenue was $16.1 million in the fourth quarter, up 21%.
- Industry and Applied: Industry and applied revenue was $6.6 million in the fourth quarter, growing 12%.
- Global Supply Partner: Global Supply Partner revenue was $15 million in the fourth quarter, an 18% increase.
Capital allocation
- The company raised $424.8 million in net proceeds through an equity offering and at-the-market sales.
This capital gives us flexibility to expand the discovery characterization capabilities prepared for MRD growth and act on emerging opportunities.
- CapEx: Capital expenditures for fiscal 2026 were $48 million.
- Future CapEx: The company expects to spend approximately $150 million in capital expenditures over fiscal 2027 and 2028, plus $30 million in landlord-funded tenant improvements.
- FY27 CapEx: Management expects capital expenditures of approximately $75 million for fiscal 2027.
Industry trends and dynamics
- The company sees a shift toward personalized healthcare, increasing the need for custom manufacturing at scale.
As health care becomes more personalized we believe the need for custom manufacturing at scale grows exponentially.
- AI-enabled drug discovery is driving demand for DNA synthesis and protein characterization as customers design more molecules.
As customers use AI to design more molecules to explore more targets the amount of experimental work they can pursue expands.
- Nucleic Acid Therapeutics: The market for nucleic acid therapeutics, including mRNA and siRNA, requires high-throughput production of unique sequences.
- MRD: Minimal Residual Disease (MRD) testing is moving toward tumor-informed panels that require high sensitivity and thousands of probes.
Competitive landscape
- The company believes its proprietary platform offers a structural advantage in cost, scale, and speed.
We believe our proprietary platform gives us a structural advantage in cost, scale and speed.
- Management noted that the company differentiates itself through its automation engineering capabilities.
Our experience in automation engineering provides added differentiation from our peers.
- The company is seeing increased adoption of AI-based approaches by traditional drug discovery companies.
We see more and more of excitement about AI.
Macroeconomic environment
- The call did not discuss the macroeconomic environment.
Growth opportunities and strategies
- AI Drug Discovery: AI drug discovery is expected to remain one of the fastest-growing product groups in fiscal 2027.
- Workflow Expansion: The company is expanding its workflow offerings, including the recent launch of a cell-free protein expression workflow.
- Nucleic Acid Therapeutics: The company is building capacity for nucleic acid therapeutics as a medium- to long-term opportunity.
- MRD: The company launched MRD Express to address the tumor-informed MRD market.
Financial guidance and outlook
- Revenue Guidance: The company expects total revenue for fiscal 2027 to be between $550 million and $560 million.
- AI Revenue: The fiscal 2027 revenue guidance includes $100 million in AI drug discovery revenue.
- Gross Margin: The company expects gross margin for fiscal 2027 to be approximately 52.5% to 53%.
- EBITDA: The company expects positive adjusted EBITDA for the full fiscal year 2027.
- Q1 Guidance: For the first quarter of fiscal 2027, the company expects revenue of $130 million to $132 million.
Operational capacity and infrastructure
- Automation: The company introduced approximately 30 automated systems and workflows in fiscal 2026.
- DNA Writers: The company currently has 10 DNA writers operating, with 2 installations planned and 4 more on order, for a total of 16.
- Capacity: Once all 16 DNA writers are operational, the company will have the capacity to manufacture more than 50 million pieces of DNA daily.
- Long-term Capacity: Planned investments aim to support more than $1 billion in annual revenue within existing facilities.
Q4 FY2026 results
| Metric | Result | Change |
|---|---|---|
| Q4 Revenue | $126.6 million | Up 28% year-over-year |
| Full Year Revenue | $459.4 million | Up 22% year-over-year |
| AI Drug Discovery Revenue (FY2026) | $59.1 million | Up 175% year-over-year |
| Q4 Adjusted EBITDA | $2.2 million | Positive |
| Full Year Gross Margin | 52.4% | Up from 50.7% in fiscal 2025 |
How management sounded
Positive (+45 on our -100 to +100 scale). Management successfully hit the adjusted EBITDA breakeven milestone, reported strong revenue growth, and expressed high confidence in their AI drug discovery pipeline and capacity expansion plans. Management sounded more upbeat than on 63% of the 302 calls we cover; most companies sound positive on their own calls, so the comparison says more than the label.
Read the analyst Q&A summary and guidance and outlook for this call.
What to watch before the next call
- Execution of the $150 million capital expenditure plan over the next two years.
- Conversion of AI drug discovery orders into revenue.
- Performance of the newly launched MRD Express product.
Earlier calls
- Q3 FY2026 (Aug 3, 2026), tone Positive: Twist Bioscience reported record revenue of $118.4 million, up 23% year-over-year, and raised its full-year revenue guidance to $456 million to $457 million while maintaining its path to adjusted EBITDA breakeven in the fourth quarter.

